Brasília – An increasing number of Brazilians are resorting to importing or purchasing through informal channels pens of Mounjaro (tirzepatide) from neighboring Paraguay, driven by limited access and high demand for anti-obesity and metabolic therapies in Brazil. The surge in cross-border acquisition highlights regulatory, supply and affordability challenges in the country’s pharmaceutical market.

Authorities report that many of the imported units bypass formal distribution and regulatory oversight, posing risks of counterfeit products, improper storage and lack of medical supervision. Customs seizures of large quantities of the medication reflect concern among enforcement agencies about patient safety and market integrity.

Experts warn that while self-importation and parallel channels may appear as short-term workarounds for patients, they undermine drug safety, compromise public-health oversight and may distort accessible treatment pathways within the regulated system.

Source: O Estado de S. Paulo

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com